Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: the Iranian Project for Assessment of Coronary Events 2 (IPACE2).

OBJECTIVES: To assess contemporary data on characteristics, management and 1-year postdischarge outcomes in Iranian patients hospitalised with acute coronary syndrome (ACS).
SETTING: 11 tertiary care hospitals in 5 major cities in the Islamic Republic of Iran. PARTICIPANTS: Patients aged ≥ 20 and ≤ 80 years discharged alive with confirmed diagnosis of ACS including ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI) and high-risk unstable angina (HR-UA). PRIMARY AND SECONDARY OUTCOME MEASURES: Patients were followed up regarding the use of medications and the end points of the study at 1 month and 1 year after discharge. The primary end point of the study was 1-year postdischarge major adverse cardiac and cerebrovascular events (MACCEs), defined as mortality (cardiac and non-cardiac), ACS and cerebrovascular attack (stroke and/or transient ischaemic attack). The secondary end points were hospital admission because of congestive heart failure, revascularisation by coronary artery bypass grafting surgery or percutaneous coronary intervention (PCI), and major and minor bleeds.
RESULTS: A total of 1799 patients (25.7% STEMI and 74.3% HR-UA/NSTEMI) discharged alive with confirmed diagnosis of ACS were included in the final analysis. During hospitalisation, the majority of the patients received aspirin (98.6%), clopidogrel (91.8%), anticoagulants (93.4%), statins (94.3%) and β-blockers (89.3%). Reperfusion therapy was performed in 62.6% of patients with STEMI (46.3% thrombolytic therapy and 17.3% primary PCI). The mean door-to-balloon and door-to-needle times were 82.9 and 45.6 min, respectively. In our study, 64.7% and 79.5% of the patients in HR-UA/NSTEMI and STEMI groups, respectively, underwent coronary angiography. During the 12 months after discharge, MACCEs occurred in 15.0% of all patients.
CONCLUSIONS: Our study showed that the composition of Iranian patients with ACS regarding the type of ACS is similar to that in developed European countries and is unlike that in developing countries of the Middle East and Africa. We found that our patients with ACS are treated with high levels of adherence to guideline-recommended in-hospital medications. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

This is the first and only study on management and outcomes of patients with acute coronary syndrome (ACS) in Iran.

In addition to assessment of in-hospital management, the patients were followed up for 1 year regarding the cardiovascular events and adherence to evidence-based treatment for ACS.

We comprehensively compared the situation of Iran regarding management and outcome of ACS with that in developed countries and developing nations of the Middle East region.

Although the study was multicentre and 11 hospitals participated, it was not a population-based registry and selection bias could have occurred.

Introduction

Acute coronary syndrome (ACS) represents a major healthcare burden worldwide. The diagnosis and management of unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI) and STEMI have been rapidly evolving in recent years.1 However, ACS continues to be a significant health problem throughout the world, being responsible for a substantial number of deaths due to cardiovascular diseases (CVDs). The status of Middle Eastern nations in this context is especially worrying, as, according to prediction by the WHO, they will face the greatest increment in the absolute burden of CVD in the world.2

In recent years, well-regarded scientific societies in Europe and the USA have developed several guidelines to improve the outcomes of ACS through implementation of recommendations into clinical practice.3–6 Most of the real-world evidence about patients with ACS comes from several large registries7–12 with data on demography, treatments and outcomes of patients in middle-income and high-income countries, and little is known about patients with ACS in developing countries. Moreover, findings of the surveys and registries performed so far demonstrate that epidemiology and management of patients with ACS differ a lot between countries, and there is a wide gap between guidelines and current clinical practice.1 7 13 14 Additionally, multinational registries often represent statistical averages for the participating centres rather than representing a real, existing geographical population.14 Hence, more representative local registries are needed in developing countries to increase awareness of CVD burden, its management and outcomes, in order to establish appropriate preventive and management strategies.

There are very limited data regarding the epidemiology, management and outcomes of ACS in Iranian patients. The Iranian Project for Assessment of Coronary Events 2 (IPACE2) was a prospective nationwide multicentre registry designed to gain insights into the epidemiology, clinical characteristics, management and 1-year postdischarge outcomes of Iranian patients hospitalised with ACS.

Materials and methods

Study participants

Between April 2011 and November 2012, we established a prospective multicentre registry that recruited patients aged ≥20 and ≤80 years with any type of ACS (STEMI, NSTEMI or high risk (HR)-UA) from 11 hospitals in five major cities in the Islamic Republic of Iran.

We obtained ethical approval before initiation of the study and all patients provided informed consent.

According to the protocol, all admitted patients with suspected ACS were screened to be eligible to enter the registry. However, we enrolled those patients with final diagnosis of ACS who were discharged alive from hospital and who gave informed consent for participation in the study. The final diagnosis was made by the attending cardiologist, based on clinical presentation, initial ECG pattern and markers of myocardial necrosis acquired at least 6 h after the symptom onset. The patients were then classified as having HR-UA, NSTEMI or STEMI. The definition of the final diagnosis was as follows:

STEMI: presence of (1) ST-segment elevation consistent with myocardial infarction (MI) of ≥2 mm in adjacent chest leads and/or ST-segment elevation of ≥1 mm in two or more standard leads or new left bundle branch block (LBBB) and (2) positive cardiac necrosis markers.

NSTEMI: (1) absence of ST-segment elevation consistent with MI of ≥2 mm in adjacent chest leads and ST-segment elevation of ≥1 mm in two or more standard leads and new LBBB and (2) positive cardiac necrosis markers.

HR-UA: (1) absence of ST-segment elevation consistent with MI of ≥2 mm in adjacent chest leads and ST-segment elevation of ≥1 mm in two or more standard leads and new LBBB and (2) negative cardiac necrosis markers and (3) angina pectoris (or equivalent type of ischaemic discomfort) with any one of the three following features: (1) angina occurring at rest and prolonged, >20 min, (2) new-onset angina of at least Canadian Cardiovascular Society (CCS) class III severity or (3) recent acceleration of angina reflected by an increase in severity of at least one CCS class to at least CCS class III.

Study protocol

A detailed protocol was prepared with inclusion and exclusion criteria, methods and logistics, and definitions of all fields in the registry dataset. Also, the representative investigators from each collaborating hospital reviewed the workflow of the protocol in steering committee meetings before the registry was started. The patient with ACS registry was designed to collect data on demographic characteristics, medical history, cardiovascular risk factors, clinical presentation, time of symptom onset, early in-hospital management, reperfusion treatment, time of admission and start of thrombolysis or balloon, findings of diagnostic tests, hospital length of stay, discharge medications, and 1-month and 1-year follow-up for medications and outcomes.

Data for this registry were gathered at each centre by investigators instructed on the use of standardised electronic case report forms (e-CRF). All investigators had a username and password specific for them and were trained on how to extract and enter data to the electronic web-based registry. During the data collection, trained clinical audits supervised the compliance with study protocol and validity of the data. Moreover, the consistency and accuracy of data entry was overseen by a qualified independent assessor.

Patients were followed up regarding the use of medications through phone calls or direct visits at 1 month and 1 year after discharge as well as at the end points of the study. For the telephone follow-up interviews, at least five attempts were made to contact participants or their first-degree relatives. If telephone interviews were unsuccessful, the participants were contacted by mail using their home address. The primary endpoint of this study was 1-year postdischarge major adverse cardiac and cerebrovascular events (MACCEs), defined as mortality (cardiac and non-cardiac), ACS and cerebrovascular attack (CVA) (stroke and/or transient ischaemic attack, TIA). The secondary end points were hospital admission because of congestive heart failure, revascularisation by coronary artery bypass grafting (CABG) surgery or percutaneous coronary intervention (PCI), and major and minor bleeds. ACS was identified as HR-UA, NSTEMI or STEMI, using the aforementioned definitions, that resulted in readmission of the patient after discharge. CVA (stroke and/or TIA) was defined as an acute neurological deficit accompanied by brain imaging compatible with a recent ischaemic or haemorrhagic event. Major bleeding was defined as overt clinical bleeding: (1) that was associated with a drop in haemoglobin of more than 5 g/dL or a haematocrit of >15% (absolute); (2) that caused haemodynamic compromise or (3) that required a blood transfusion.

Adherence to guideline-recommended antiplatelet treatment was defined based on the recommendations of the “2011 American College of Cardiology (ACC)/American Heart Association (AHA) Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction”3 and “2009 Focused Updates of ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction,”4 for antiplatelet treatment on admission and after discharge in any subgroup of patients with ACS. Full adherence was defined as receiving antiplatelet treatment in compliance with the guideline at all time points (at discharge, 1 month after discharge and 1 year after discharge).

Role of the funding source

Sanofi-Aventis Groupe Iran Affiliate was the sponsor for this study. The sponsor had significant contribution in study design and preparation of the logistics. However, it had no role in data analysis, data interpretation or writing of the report. The Steering Committee, which was composed of investigators and an agent of the sponsor, was involved in the preparation and approval of the protocol, and supervised the conduct of study. The committee had full access to all the data in the study and was given full authority for presentation and publication of the results.

Statistical analysis

The Kolmogorov-Smirnov test was applied to examine normal distribution. The continuous variables are expressed as mean±SD and were compared between the STEMI/new LBBB and HR-UA/NSTEMI groups, using the Student t test. The categorical variables were compared using a χ2 test or the Fisher exact test, as appropriate, and they are presented as absolute frequencies with percentages. Multiple logistic regression analyses were used to determine independent predictors of MACCEs in patients with STEMI/new LBBB and also in patients with HR-UA/NSTEMI at 1 year after discharge. Variables were entered into the logistic regression model based on their statistical significance in univariable analyses (entering the criterion p≤0.1) as well as on their clinical significance (based on the investigators’ discretion). The final included variables in the model were heart rate on admission, positive histories of diabetes mellitus (DM), and/or peripheral arterial disease, PCI or CABG during the admission or 1-year postdischarge, congestive heart failure during admission or 1-year postdischarge, left ventricular ejection fraction (LVEF)<40%, left main disease or multivessel coronary artery disease in coronary angiography and full adherence to guideline-recommended antiplatelet therapy throughout the first year after ACS. Moreover, we also included sex, typical chest pain at presentation, history of CVA, reperfusion therapy and anterior STEMI in the STEMI/new LBBB group. For all analyses, the statistical package SPSS V.16.0 for Windows (SPSS Inc, Chicago, Illinois, USA) was used. All p values were two-tailed with significance defined as p≤0.05.

Results

Study population

Between April 2011 and November 2012, 1997 patients with suspected ACS were recruited from 20 teaching hospitals in five major cities of Iran. Of the 1997 patients recruited, 1799 patients were discharged alive with confirmed diagnosis of ACS: 855 from Tehran (47.5%); 377 from Mashhad (21.0%); 167 from Tabriz (9.3%); 206 from Isfahan (11.5%) and 194 from Shiraz (10.8%). One year follow-up was successfully completed in 1640 patients, for an overall follow-up rate of 91.2%.

Discharge diagnoses were STEMI/new LBBB in 463 patients (25.7%) and HR-UA/NSTEMI in 1336 patients (74.3%). Of the patients with UA/NSTEMI, 377 (20.9%) had NSTEMI and 959 (53.3%) had HR-UA. Table 1 shows the baseline demographic and clinical characteristics of these groups. For the entire patient group, the mean (±SD) age was 60.1 (±11.2) years and 65.4% were male. Patients with HR-UA/NSTEMI tended to have more concomitant diseases including hypertension, hyperlipidaemia, DM and histories of UA, MI, PCI, CABG and peripheral arterial disease than did patients with STEMI/new LBBB. However, patients with STEMI/new LBBB were more likely to be men, younger and current smokers, and to present with typical ischaemic chest pain.

Table 1

Baseline demographic and clinical characteristics of the study patients

Characteristics	Total (n=1799)	STEMI/new LBBB (n=463)	UA/NSTEMI (n=1336)	p Value
Demographics
Age, year	60.1±11.2	58.8±11.3	60.5±11.1	0.004
Male sex, n (%)	1177 (65.4)	371 (80.1)	806 (60.3)	<0.0001
Presenting characteristics
Ischaemic-type chest pain, n (%)	1638 (91.1)	445 (96.1)	1193 (89.3)	<0.0001
Cardiac arrest/ASCD, n (%)	2 (0.1)	2 (0.4)	0 (0.0)	0.066
Heart rate, bpm	78.6±17.3	78.7±16.6	78.5±17.6	0.829
SBP, mm Hg	135.4±25.6	133.9±26.7	135.9±25.2	0.140
DBP, mm Hg	82.2±15.0	82.6±16.2	82.1±14.6	0.585
Risk factors, n (%)
Hypertension	898 (49.9)	183 (39.5)	715 (53.6)	<0.0001
Hyperlipidaemia	826 (45.9)	159 (34.9)	667 (50.5)	<0.0001
Diabetes mellitus	559 (31.1)	120 (25.9)	439 (32.9)	<0.0001
Family history of CAD	510 (28.4)	119 (27.4)	391 (31.0)	0.150
Smoking
Current	530 (29.5)	199 (43.0)	331 (24.8)	<0.0001
Past	184 (10.2)	41 (8.9)	143 (10.7)
Medical history, n (%)
UA	797 (44.3)	119 (26.0)	678 (51.4)	<0.0001
MI	330 (18.3)	60 (13.1)	270 (20.6)	<0.0001
PCI	196 (10.9)	31 (6.7)	165 (12.4)	0.001
CABG	158 (8.8)	14 (3.0)	144 (10.8)	<0.0001
CVA	93 (5.2)	20 (4.3)	73 (5.5)	0.324
PAD	30 (1.7)	3 (0.7)	27 (2.3)	0.034

All plus-minus values are mean±SD.

ASCD, aborted sudden cardiac death; CABG, coronary artery bypass grafting surgery; CAD, coronary artery disease; CVA, cerebrovascular attack; DBP, diastolic blood pressure; LBBB, left bundle branch block; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina.

In-hospital medications and interventions

Table 2 shows the prescription of guideline-recommended medications in the first 24 h of admission in the entire patient group. Aspirin and clopidogrel were given to 98.6% and 91.8%, respectively, and 91.2% of the patients received dual antiplatelet therapy (DAPT). Patients with STEMI/new LBBB were more likely to receive clopidogrel as well as DAPT than were patients with HR-UA/NSTEMI. Overall, 94.3% of the patients were treated with statins and 89.3% received β-blockers. ACE inhibitors or angiotensin receptor blockers were administered in 81.9% of all patients, and 93.4% received anticoagulation therapy with almost similar proportions of intravenous unfractionated heparin and subcutaneous low-molecular-weight heparin.

Table 2

In-hospital medication administered for the study patients

Characteristics	Total (n=1799)	STEMI/new LBBB (n=463)	UA/NSTEMI (n=1336)	p Value
Medications, n (%)
Aspirin	1773 (98.6)	460 (99.4)	1313 (98.3)	0.095
Clopidogrel	1652 (91.8)	454 (98.1)	1198 (89.7)	<0.0001
Other antiplatelets	15 (0.8)	6 (1.3)	9 (0.7)	0.235
Dual antiplatelet therapy	1640 (91.2)	452 (97.6)	1188 (88.9)	<0.0001
UFH	864 (48.0)	230 (49.7)	634 (47.5)	0.410
LMWH	817 (45.4)	197 (42.5)	620 (46.4)	0.151
Statin	1697 (94.3)	441 (95.2)	1256 (94.0)	0.322
β-blocker	1606 (89.3)	421 (90.9)	1185 (88.7)	0.181
ACEI/ARB	1473 (81.9)	403 (87.0)	1070 (80.1)	0.001
Nitrates	1653 (91.9)	417 (90.1)	1236 (92.5)	0.096
Oral antiglycaemic agents	228 (12.7)	36 (7.8)	192 (14.4)	<0.0001
PPIs	746 (41.5)	206 (44.5)	540 (40.4)	0.125

ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; LBBB, left bundle branch block; LMWH, low-molecular-weight heparin; NSTEMI, non-ST-segment elevation myocardial infarction; PPIs, proton-pump inhibitors; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina; UFH, unfractionated heparin.

Among patients with STEMI/new LBBB, 290 (62.6%) underwent reperfusion therapy; 46.3% of the patients with STEMI/new LBBB received thrombolytic therapy, which was mostly streptokinase (table 3), and primary PCI was carried out in 17.3% of the patients with STEMI/new LBBB. The mean door-to-balloon and door-to-needle times were 82.9 and 45.6 min, respectively. Iranian patients with ACS had a mean 265.6 min delay from symptom onset to presenting to a hospital.

Table 3

In-hospital reperfusion and revascularisation strategies in the study patients

Characteristics	Total (n=1799)	STEMI/new LBBB (n=463)	UA/NSTEMI (n=1336)	p Value
Reperfusion strategies, n (%)
No reperfusion	–	153 (33.6)	–	–
Primary CABG	–	13 (2.9)	–	–
Thrombolytic therapy	–	211 (46.3)	–	–
Symptom onset to thrombolytic	–	269.0±477.3	–	–
Door-to-needle time	–	45.6±41.1	–	–
Primary PCI	–	79 (17.3)	–	–
Symptom onset to PCI	–	256.8±186.6	–	–
Door-to-balloon time	–	82.8±112.5	–	–
Revascularisation strategies, n (%)
Coronary angiography	1232 (68.5)	368 (79.5)	864 (64.7)	<0.0001
PCI (excluding primary PCI)	360 (20.0)	133 (28.7)	227 (17.0)	<0.0001
DES	258 (71.9)	94 (70.1)	164 (72.9)	0.764
BMS	81 (22.6)	33 (24.6)	48 (21.3)
Both	20 (5.5)	7 (5.2)	13 (5.8)
CABG surgery	180 (10.0)	34 (7.3)	146 (10.9)	0.049

All plus-minus values are mean±SD.

BMS, bare metal stent; CABG, coronary artery bypass grafting surgery; DES, drug-eluting stent; LBBB, left bundle branch block; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina.

In the HR-UA/NSTEMI group, invasive strategy (coronary angiography) was applied in about two-thirds of the patients, while 79.5% of the patients in STEMI/new LBBB group underwent coronary angiography. Elective PCI during hospital stay was performed in 20.0% of all patients. Among the patients who underwent PCI, 71.9% received drug-eluting stents, 22.6% received bare-metal stents and 5.5% received both types of stents. During the hospital stay, 10.0% of the patients underwent CABG surgery.

Postdischarge adherence to antiplatelet therapy

Table 4 shows the compliance with guideline-recommended antiplatelet treatment for patients with ACS at discharge, and 1 month and 1 year after discharge. At discharge, 77.5% of the patients with STEMI/new LBBB received guideline-compliant antiplatelets, but this amount gradually decreased and only about half of the patients with STEMI/new LBBB had full adherence to guideline-recommended antiplatelet treatment at 1 year. In the HR-UA/NSTEMI group, 67.0% were discharged with guideline-recommended antiplatelet regimens, but only 28.3% of the patients were using antiplatelets in compliance with the guideline for the entire 12 months after discharge. Moreover, at discharge and 1 and 12 months after discharge, the patients who had undergone PCI or CABG during index hospitalisation were more likely than patients scheduled for conservative management to receive antiplateletes according to the ACC/AHA recommendations for antiplatelet treatment in patients with ACS.

Table 4

Adherence to postdischarge guideline-recommended antiplatelet therapy

	At discharge		1 Month after discharge		1 Year after discharge		Full adherence
	Yes	No	Yes	No	Yes	No	Yes	No
STEMI/new LBBB	359 (77.5)	104 (22.5)	322 (72.4)	123 (27.6)	207 (51.8)	193 (48.3)	197 (49.7)	199 (50.3)
Revascularisation*	210 (85.0)	37 (15.0)	193 (80.4)	47 (19.6)	141 (64.1)	79 (35.9)	139 (63.5)	80 (36.5)
Conservative management	149 (69.0)	67 (31.0)	129 (62.9)	76 (37.1)	66 (36.7)	114 (63.3)	58 (32.8)	119 (67.2)
UA/NSTEMI	895 (67.0)	441 (33.0)	753 (58.6)	533 (41.4)	424 (37.9)	695 (62.1)	313 (28.3)	792 (71.7)
Revascularisation*	300 (77.7)	86 (22.3)	288 (76.6)	88 (23.4)	156 (46.0)	183 (54.0)	105 (31.3)	230 (68.7)
Conservative management	595 (62.6)	355 (37.4)	465 (51.1)	445 (48.9)	268 (34.4)	512 (65.6)	208 (27.0)	562 (73.0)
Total	1254 (69.7)	545 (30.3)	1075 (62.1)	656 (37.9)	631 (41.5)	888 (58.5)	510 (34.0)	991 (66.0)
Revascularisation*	510 (80.6)	123 (80.6)	481 (78.1)	135 (21.9)	297 (53.1)	262 (46.9)	244 (44.0)	310 (56.0)
Conservative management	744 (63.8)	422 (36.2)	594 (53.3)	521 (46.7)	334 (34.8)	626 (65.2)	266 (28.1)	681 (71.9)

* PCI or CABG during index hospitalisation.

CABG, coronary artery bypass grafting surgery; LBBB, left bundle branch block; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina.

Postdischarge outcomes

Table 5 demonstrates the 1-year postdischarge outcomes of the study patients. During the entire study period, 70 patients died (22 in the STEMI/new LBBB group and 48 in the HR-UA/NSTEMI group). Although 1-year total postdischarge mortality did not show significant difference between the two groups, the cardiovascular mortality was higher in patients with STEMI/new LBBB than in patients with HR-UA/NSTEMI, with statistically borderline significance (5.2% vs 3.9%, respectively, p=0.061). Moreover, patients with STEMI/new LBBB were more likely to undergo PCI (15.9% vs 7.7%) or CABG (9.0% vs 6.5%) after discharge. During the 12-months follow-up, MACCEs occurred in 15.0% of all patients and the rate of the MACCE was similar in the STEMI/new LBBB and HR-UA/NSTEMI groups. Of the entire patient group, 1.4% experienced at least one episode of bleeding during 1-year follow-up, of which 30.4% were major bleeds. Patients with STEMI/new LBBB and HR-UA/NSTEMI were found to have similar rates of bleeding, and of similar severity, during the 12 months after discharge.

Table 5

One year postdischarge outcomes of the study patients

Characteristics	Total (n=1640)	STEMI/new LBBB (n=421)	UA/NSTEMI (n=1219)	p Value
Mortality	70 (4.3)	22 (5.2)	48 (3.9)	0.267
Cardiac	50 (71.4)	19 (86.4)	31 (64.6)	0.061
Non-cardiac	20 (28.6)	3 (13.6)	17 (35.4)
Acute coronary syndrome	156 (9.5)	36 (8.5)	120 (9.8)	0.427
Congestive heart failure	54 (3.3)	12 (2.8)	42 (3.4)	0.551
CABG	117 (7.1)	38 (9.0)	79 (6.5)	0.081
PCI	161 (9.8)	67 (15.9)	94 (7.7)	<0.0001
Stroke/TIA	20 (1.2)	5 (1.2)	15 (1.2)	0.940
Bleeding	23 (1.4)	6 (1.4)	17 (1.4)	0.969
Severe	7 (30.4)	2 (33.3)	5 (29.4)
Moderate	4 (17.4)	1 (16.7)	3 (17.6)
Mild	12 (52.2)	3 (50.0)	9 (52.9)
MACCE*	246 (15.0)	63 (14.9)	183 (15.0)	0.996

*MACCE including stroke/TIA, acute coronary syndrome and mortality.

CABG, coronary artery bypass grafting surgery; LBBB, left bundle branch block; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischaemic attack; UA, unstable angina.

Predictors of a 1-year postdischarge MACCE

Table 6 shows the independent predictors of MACCEs during 1-year follow-up in the STEMI/new LBBB and HR-UA/NSTEMI groups separately. In the patients with STEMI/new LBBB, LVEF≤40% was associated with increased risk of a MACCE at 1-year postdischarge (OR 1.69; 95% CI, 1.03 to 2.75, p=0.036). Typical ischaemic chest pain at presentation was independently associated with lower risk of a MACCE at 12 months after discharge in patients with STEMI (OR 0.24; 95% CI, 0.09 to 0.62, p=0.003). CABG during the index hospitalisation or later during the first year after discharge was associated with lower risk of a MACCE at 1 year but the statistical significance was borderline (OR 0.27, p=0.087). Among the patients with HR-UA/NSTEMI, (a positive history of) DM, a high heart rate at presentation and history of PCI were associated with significantly increased risk of a MACCE at 12 months after discharge; revascularisation during index hospitalisation was, rather, associated with a lower MACCE risk (OR 0.356, 95% CI, 0.233 to 0.543, p<0.0001).

Table 6

Independent predictors of the major adverse cardiovascular events during 1-year postdischarge in patients with STEMI/new LBBB and HR-UA/NSTEMI

Variable	STEMI/new LBBB		UA/NSTEMI
	OR (95% CI)	p Value	OR (95% CI)	p Value
Ischaemic-type chest pain	0.24 (0.09 to 0.62)	0.003	–	–
Heart rate (bpm)	–	–	1.01 (1.000 to 1.016)	0.048
Diabetes mellitus	–	–	2.23 (1.64 to 3.03)	<0.0001
Hx of PCI before admission	–	–	1.61 (1.06 to 2.44)	0.025
Revascularisation*	–	–	0.356 (0.233 to 0.543)	<0.0001
LVEF <40%	1.69 (1.03 to 2.75)	0.036	–	–

*PCI or CABG during index hospitalisation.

CABG, coronary artery bypass grafting surgery; HR-UA, high-risk unstable angina; Hx, history; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.

Discussion

The IPACE2 study is the first to evaluate the clinical characteristics, and contemporary diagnostic and therapeutic strategies applied to patients with ACS in Iran. In addition, this survey sheds light on the mid-term prognosis and its predictors in a wide spectrum of ‘real world’ Iranian patients with ACS.

In our study, almost one-fourth (25.7%) of patients with ACS had STEMI, which is similar to proportions reported from developed countries,14–16 and it is significantly lower than the values reported from Gulf countries (45.6%), India (60%), and developing countries in Latin America and Africa17–20 (table 7). This outcome is likely to be the result of overall younger age (56–57 vs 60.1 years, respectively) and also higher male/female ratio of the patients with ACS in these countries than in ours (3.73 vs 1.89, respectively). Moreover, several factors in addition to the younger age of the population in Arabian countries—including the significantly higher prevalence of DM (39.5% vs 31.1%) and current or past smoking (52.9% vs 39.7%)—in their studied population, not as considerable in ours, may be accountable for the observed difference. However, with a mean age of 60.1 years, participants in our study were significantly younger than those in the developed countries.1 14 16 17 21 22

Table 7

Comparison of baseline characteristics, management and outcomes of acute coronary syndrome patients in developed and developing countries

	NRMI	Expanded GRACE	EHS 2	PL-ACS	Portuguese Registry of ACS	PACIFIC	CREATE	SPACE	ACCESS	GULF-RACE2	IPACE2
Sampling Period	1990–2006	2001–2007	2004	2003–2006	2002–2008	2008–2009	2002–2005	2005–2007	2007–2008	2008–2009	2011–2012
Source of data	USA	Multinational	Europe and mediterranean basin	Poland	Portugal	Japan	India	Saudi Arabia	Developing countries	Gulf countries	Iran
Patients, n	2 515 106	31 982	6385	100 193	22 482	3597	31 982	5055	12 068	7930	1799
Mean age, years	65	65	64	65	66	67	57	58	59	56	60
Male, %	58	NA	70	60	70	77	76	77	73	79	65
Current smoking, %	24	NA	37	27	24	NS	28	33	40	36	29
DM, %	29	26	24	23	27	35	30	58	24	39	31
STEMI, %	47	30	47	31	45	59	61	41.5	46	46	26
UA/NSTEMI, %	53	70	53	69	55	41	39	58.5	54	54	74
Symptom onset to hospital arrival time, (min)*	96	133	145	260	177	NA	300	150	240	176	160
Door-to-needle time, (min)*	29	32	37	25	60	NA	50	52	NA	39	30
Door-to-balloon time, (min)*	79	110	70	50	96	NA	NA	NA	NA	87	53
Thrombolytic therapy, %	28	33	41	9.3	44	NA	58.5	69.1	39	66	46
Primary PCI, %	43	16	58	54	19	63	8	17.5	22	22.3	17
Coronary angiography†, %	78	70	66	39	61	96	23	67	58	32	68
30-day mortality, %	NA	NA	6.4/3.4	NA	NA	NA	8.6/3.8	NA	5/2.4	9.9/5	2.5/1.0
1-year mortality, %	NA	NA	7.5	NA	NA	3/2.2	NA	NA	8.4/6.3	11.5/7.7	5.2/3.9

*Times in patients with STEMI.

†During index hospitalisation.

CREATE, treatment and outcomes of acute coronary syndromes in India; DM, diabetes mellitus; EHS2, European heart survey II; GRACE, global registry of acute coronary events; GULF-RACE2, gulf registry of acute coronary events-phase 2; IPACE2, Iranian Project for Assessment of Coronary Events 2; NA, not available; NRMI, national registry of myocardial infarction; NS, not significant; PACIFIC, prevention of atherothrombotic incidents following ischemic coronary attack; PCI, percutaneous coronary intervention; PL-ACS, Polish Registry of Acute Coronary Syndromes; SPACE, Saudi project for assessment of coronary events; STEMI, ST-segment elevation myocardial infarction; UA/NSTEMI, unstable angina/non-ST-segment elevation myocardial infarction.

The latest ACC/AHA guidelines for management of patients with STEMI recommends ≤30 min for door-to-needle time, ≤90 min for door-to-balloon time and ≤120 min for total ischaemic time, as the goal of reperfusion timing.4 Although our patients with STEMI were reperfused within acceptable lengths of time with respect to median door-to-needle time (mean: 45.6 min/median: 30 min) and door-to-balloon time (mean: 82.8 min, median: 53 min), it took an average of about 265 min (median: 160 min) for our patients with STEMI to reach the emergency department, which is higher than median times reported from developed countries.1 16 21 The causes responsible for long delays before hospital arrival of patients with STEMI in the Iranian population should be elucidated in future studies.

Similar to recent trends reported by other ACS registries,1 8 10 16 17 21 23–26 our study showed high compliance with guideline-recommended medications in the first 24 h of admission in Iranian patients with ACS, which demonstrates the good knowledge, attitude and practice of Iranian physicians with respect to the guideline-recommended in-hospital management of patients with ACS.

Despite the established beneficial effect of DAPT on outcomes of ACS and current ACC/AHA recommendations regarding antiplatelet treatment in patients with ACS,3 4 global experiences have shown underutilisation of dual antiplatelet agents in patients with ACS, especially in those who were diagnosed as having acute MI and those who did not undergo PCI.1 10 14 18 19 24 25 27 28 In our study, 91.8% of all patients, including 98.1% of the patients with STEMI/new LBBB and 89.7% of the patients with HR-UA/NSTEMI, received clopidogrel during the hospitalisation for ACS, which is significantly higher than previously reported values from other registries.1 10 14 18 19 24 25 27 28 However, only 69.7% of our patients with ACS, including 77.5% of the patients with STEMI/new LBBB and 67.0% of the patients with HR-UA/NSTEMI, were prescribed DAPT at discharge, and these values progressively declined over time. In the IPACE2 study, only half of the patients in the STEMI/new LBBB group and one-third of the patients in the HR-UA/NSTEMI group who were discharged with DAPT, completed the treatment for 1 year. Given the weight of evidence supporting DAPT use throughout the wide spectrum of ACS, there is a substantial opportunity to reinforce the appropriate use of these medications in the management of the spectrum of ACS to improve clinical outcome.

In this study, we observed that patients with STEMI/new LBBB and HR-UA/NSTEMI had similar incidence of all-cause mortality and MACCE during the year after discharge. However, cardiovascular mortality was significantly higher in patients with STEMI/new LBBB than in patients with HR-UA/NSTEMI and, conversely, non-cardiac mortality was higher among patients with HR-UA/NSTEMI than among the STEMI/new LBBB group. This finding is in agreement with Polonski et al,14 who observed an adjusted worse long-term prognosis in patients with STEMI than that in patients with NSTEMI. The reasons for higher mid-term non-cardiac mortality in patients with HR-UA/NSTEMI might be: (1) older age of patients with HR-UA/NSTEMI than those in the STEMI/new LBBB group and (2) higher prevalence of major comorbidities in the HR-UA/NSTEMI group, such as DM, hypertension and hyperlipidaemia, which are associated with worse prognosis and mortality.

In this study, we observed that presentation of STEMI with a typical ischaemic chest pain was associated with a decreased risk of a MACCE at 1-year postdischarge. This finding supports and expands the findings by Canto et al,29 which revealed that patients with MI without typical chest pain were less quickly diagnosed and treated, and had higher adjusted odds of hospital mortality, regardless of whether they had ST-segment elevation. The authors observed that patients without typical chest pain/discomfort were less likely to receive medications with established survival benefits and/or undergo timely reperfusion.29 In this IPACE2 study, we observed that DM significantly increased the risk of 1-year postdischarge MACCE in patients with HR-UA/NSTEMI. Our finding supports and expands the study by Chong et al,30 which observed that DM increases the risk of a MACCE at 1 and 6 months after discharge in patients with UA/NSTEMI. Park et al31 also observed that DM is a predictor of early and late cardiac death in patients with NSTEMI (and not STEMI). This suggests that, among the traditional risk factors, presence of diabetes may be the most predictive factor for adverse clinical events after discharge in patients with HR-UA/NSTEMI.

The merits of our study are that it is the first and only study on management and outcomes of patients with ACS in Iran. However, our study had several limitations. First, although the study was multicentred, with 20 hospitals participating, it was not a population-based registry and selection bias could have occurred. Second, there is an inherent selection bias because of the observational nature of the study design and the possibility of important unmeasured covariables having been missed. Finally, although we compared our data with other international ACS registries, caution has to be taken about making absolute inferences, mainly because of the patient age and timing differences between these studies and ours.

In conclusion, the IPACE2 study showed that composition of Iranian patients with ACS regarding the type of ACS is similar to that in developed European countries and is unlike that in developing countries of the Middle East and Africa. We found that our patients with ACS are treated with high levels of adherence to guideline-recommended in-hospital medications, but there was a substantial underuse of DAPT at discharge, and it also progressively declined over time after discharge. Moreover, Iranian patients with STEMI delayed a long time before presenting to the hospital, but in-hospital reperfusions were quite timely.